Adverse events during first-line treatments for mCRC : The Toxicity over Time (ToxT) analysis of three randomised trials
Copyright © 2023 Elsevier Ltd. All rights reserved..
BACKGROUND: In clinical trials, the assessment of safety is traditionally focused on the overall rate of high-grade and serious adverse events (AEs). A new approach to AEs evaluation, taking into account chronic low-grade AEs, single patient's perspective, and time-related information, such as ToxT analysis, should be considered especially for less intense but potentially long-lasting treatments, such as maintenance strategies in metastatic colorectal cancer (mCRC).
PATIENTS AND METHODS: We applied ToxT (Toxicity over Time) evaluation to a large cohort of mCRC patients enroled in randomised TRIBE, TRIBE2, and VALENTINO studies, in order to longitudinally describe AEs throughout the whole treatment duration and to compare AEs evolution over cycles between induction and maintenance strategies, providing numerical and graphical results overall and per single patient. After 4-6 months of combination therapy, 5-fluorouracil/leucovorin (5-FU/LV) + bevacizumab or panitumumab was recommended in all studies except for the 50% of patients in the VALENTINO trial who received panitumumab alone.
RESULTS: Out of 1400 patients included, 42% received FOLFOXIRI (5-FU/LV, oxaliplatin, and irinotecan)/bevacizumab, 18% FOLFIRI/bevacizumab, 24% FOLFOX/bevacizumab, 16% FOLFOX/panitumumab. Mean grade of general and haematological AEs was higher in the first cycles, then progressively decreasing after the end of induction (p < 0.001), and always remaining at the highest levels with FOLFOXIRI/bevacizumab (p < 0.001). Neurotoxicity became more frequent over the cycles with late high-grade episodes (p < 0.001), while the incidence but not the grade of hand-and-foot syndrome gradually increased (p = 0.91). Anti-VEGF-related AEs were more severe in the first cycles, then setting over at low levels (p = 0.03), while anti-EGFR-related AEs still affected patients during maintenance.
CONCLUSIONS: Most of chemotherapy-related AEs (except for HFS and neuropathy) reach the highest level in the first cycles, then decrease, probably due to their active clinical management. Transition to maintenance allows relief from most AEs, especially with bevacizumab-based regimens, while anti-EGFR-related AEs may persist.
| Errataetall: |
CommentOn: Lancet Haematol. 2020 Jun;7(6):e490-e497. - PMID 32470440 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:189 |
|---|---|
| Enthalten in: |
European journal of cancer (Oxford, England : 1990) - 189(2023) vom: 29. Aug., Seite 112910 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boccaccino, Alessandra [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.07.2023 Date Revised 04.12.2023 published: Print-Electronic CommentOn: Lancet Haematol. 2020 Jun;7(6):e490-e497. - PMID 32470440 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejca.2023.05.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358034574 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358034574 | ||
| 003 | DE-627 | ||
| 005 | 20231226073900.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2023.05.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1193.xml |
| 035 | |a (DE-627)NLM358034574 | ||
| 035 | |a (NLM)37301718 | ||
| 035 | |a (PII)S0959-8049(23)00229-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boccaccino, Alessandra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adverse events during first-line treatments for mCRC |b The Toxicity over Time (ToxT) analysis of three randomised trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.07.2023 | ||
| 500 | |a Date Revised 04.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Lancet Haematol. 2020 Jun;7(6):e490-e497. - PMID 32470440 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: In clinical trials, the assessment of safety is traditionally focused on the overall rate of high-grade and serious adverse events (AEs). A new approach to AEs evaluation, taking into account chronic low-grade AEs, single patient's perspective, and time-related information, such as ToxT analysis, should be considered especially for less intense but potentially long-lasting treatments, such as maintenance strategies in metastatic colorectal cancer (mCRC) | ||
| 520 | |a PATIENTS AND METHODS: We applied ToxT (Toxicity over Time) evaluation to a large cohort of mCRC patients enroled in randomised TRIBE, TRIBE2, and VALENTINO studies, in order to longitudinally describe AEs throughout the whole treatment duration and to compare AEs evolution over cycles between induction and maintenance strategies, providing numerical and graphical results overall and per single patient. After 4-6 months of combination therapy, 5-fluorouracil/leucovorin (5-FU/LV) + bevacizumab or panitumumab was recommended in all studies except for the 50% of patients in the VALENTINO trial who received panitumumab alone | ||
| 520 | |a RESULTS: Out of 1400 patients included, 42% received FOLFOXIRI (5-FU/LV, oxaliplatin, and irinotecan)/bevacizumab, 18% FOLFIRI/bevacizumab, 24% FOLFOX/bevacizumab, 16% FOLFOX/panitumumab. Mean grade of general and haematological AEs was higher in the first cycles, then progressively decreasing after the end of induction (p < 0.001), and always remaining at the highest levels with FOLFOXIRI/bevacizumab (p < 0.001). Neurotoxicity became more frequent over the cycles with late high-grade episodes (p < 0.001), while the incidence but not the grade of hand-and-foot syndrome gradually increased (p = 0.91). Anti-VEGF-related AEs were more severe in the first cycles, then setting over at low levels (p = 0.03), while anti-EGFR-related AEs still affected patients during maintenance | ||
| 520 | |a CONCLUSIONS: Most of chemotherapy-related AEs (except for HFS and neuropathy) reach the highest level in the first cycles, then decrease, probably due to their active clinical management. Transition to maintenance allows relief from most AEs, especially with bevacizumab-based regimens, while anti-EGFR-related AEs may persist | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a Adverse events | |
| 650 | 4 | |a FOLFOXIRI | |
| 650 | 4 | |a Metastatic colorectal cancer | |
| 650 | 4 | |a Toxicity over Time (ToxT) | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 650 | 7 | |a Panitumumab |2 NLM | |
| 650 | 7 | |a 6A901E312A |2 NLM | |
| 650 | 7 | |a Camptothecin |2 NLM | |
| 650 | 7 | |a XT3Z54Z28A |2 NLM | |
| 650 | 7 | |a Fluorouracil |2 NLM | |
| 650 | 7 | |a U3P01618RT |2 NLM | |
| 650 | 7 | |a Leucovorin |2 NLM | |
| 650 | 7 | |a Q573I9DVLP |2 NLM | |
| 700 | 1 | |a Rossini, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Raimondi, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Carullo, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Lonardi, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Morano, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Santini, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Tomasello, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Niger, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Zaniboni, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Daniel, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Bustreo, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Procaccio, Letizia |e verfasserin |4 aut | |
| 700 | 1 | |a Clavarezza, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Cupini, Samanta |e verfasserin |4 aut | |
| 700 | 1 | |a Libertini, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Palermo, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Pietrantonio, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Cremolini, Chiara |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer (Oxford, England : 1990) |d 1991 |g 189(2023) vom: 29. Aug., Seite 112910 |w (DE-627)NLM012602779 |x 1879-0852 |7 nnns |
| 773 | 1 | 8 | |g volume:189 |g year:2023 |g day:29 |g month:08 |g pages:112910 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2023.05.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 189 |j 2023 |b 29 |c 08 |h 112910 | ||